Asston Pharmaceuticals IPO open date is July 9, 2025 and the IPO will close on July 11, 2025.
The company reported revenue of ₹25.61 crores and profit of ₹4.33 crores in 2025.
Asston Pharmaceuticals was established in April 2019 and converted into a public company in August 2024. It has grown from a formulation trader to a WHO-GMP certified manufacturer exporting to Africa and Asia.
Incorporation: April 16, 2019, as Asston Pharmaceuticals Private Limited.
Conversion to Public Limited: August 29, 2024.
Headquarters: Navi Mumbai, Maharashtra.
Manufacturing Unit: WHO-GMP and FDA-approved facility at Ambernath, Maharashtra.
Milestones:
- FY21: Crossed ₹10 Cr revenue.
- FY22–24: Export expansion to Ghana, Liberia, Cambodia, Vietnam.
- FY24: Acquisition of Ferron Lifecare Private Ltd (nutraceuticals).
- 8M FY25: Substantial increase in revenue and net profit before IPO.
Asston Pharmaceuticals IPO Details
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹115 to ₹123 Per Share |
| Issue Size: | Approx ₹27.56 Crores |
| Fresh Issue: | Approx ₹27.56 Crores |
| Issue Type: | Book Build Issue |
| IPO Listing: | BSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
Asston Pharmaceuticals IPO Market Lot
The Asston Pharmaceuticals IPO minimum market lot is 2,000 shares with ₹2,46,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,46,000 |
| Retail Maximum | 2 | 2,000 | ₹2,46,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,69,000 |
Asston Pharmaceuticals IPO Dates
The Asston Pharmaceuticals IPO date is July 9 and the close date is July 11.
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Basis of Allotment: | July 14, 2025 |
| Refunds: | July 15, 2025 |
| Credit to Demat Account: | July 15, 2025 |
| IPO Listing Date: | July 16, 2025 |
Asston Pharmaceuticals IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2023 | ₹7.19 | ₹5.78 | ₹1.06 | ₹13.69 |
| 2024 | ₹15.84 | ₹14.02 | ₹1.36 | ₹20.26 |
| 2025 | ₹25.61 | ₹19.91 | ₹4.33 | ₹28.12 |
| May 2025 | ₹6.21 | ₹4.44 | ₹1.32 | ₹31.83 |
Asston Pharmaceuticals IPO Valuation – FY2025
Check Asston Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 50.56% |
| ROCE: | 51.25% |
| EBITDA Margin: | 24.60% |
| PAT Margin: | 17.27% |
| Debt to equity ratio: | 0.68 |
| Earning Per Share (EPS): | ₹6.90 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 40.36% |
| Net Asset Value (NAV): | ₹17.09 |
Business Overview of Asston Pharmaceuticals Manufacture
Asston Pharmaceuticals manufactures and exports pharma formulations and nutraceuticals. Its revenue is driven mainly by exports to Africa and Southeast Asia, with additional income from domestic sales and contract manufacturing.
- Core Activities:
- Manufacturing & exporting formulations and nutraceutical products.
- Product lines: Tablets, capsules, syrups, ointments, powders, sachets, oral liquids.
- Revenue Streams:
- Exports (~majority): Especially to Africa (Sierra Leone, Liberia, Ghana).
- Domestic Sales: Limited.
- Loan Licensing/Contract Manufacturing.
- Certifications:
- WHO-GMP compliant.
- FDA license for Ambernath plant.
- Geographical Reach:
- International: Africa (Ghana, Liberia), Southeast Asia (Cambodia, Vietnam).
- Domestic: Operations in Maharashtra.
Industry & Market Overview
India is the 3rd largest pharma producer by volume and the market is expected to grow to $130 billion by 2030. Asston operates in a competitive generics market, benefitting from global demand and regulatory approvals.
- India Pharma Industry Highlights:
- 3rd largest by volume globally.
- Market expected to grow from $50 Bn in 2023 to $130 Bn by 2030.
- India supplies:
- 20% of global generics.
- 60% of vaccine demand.
- 40% of U.S. generics.
- Growth Drivers:
- Government’s PLI Scheme.
- Increasing global demand for affordable generics.
- India’s status as a hub for biosimilars and API production.
- Challenges:
- Regulatory scrutiny (USFDA, WHO).
- Margin pressure due to intense competition.
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Shelter Pharma Limited | 6.26 | 6.70 | 16.94% | 36.96 | – Cr. |
| Bafna Pharmaceuticals Limited | 1.76 | 51.38 | 4.89% | 35.86 | – Cr. |
| Trident Lifeline Limited | 11.35 | 25.29 | 19.85% | 57.16 | – Cr. |
Asston Pharmaceuticals Promoters & Management
The company is promoted by Dr. Ashish Sakalkar, Saili More, and Sachin Badakh. No legal or regulatory issues are reported. Promoter shareholding will dilute post-IPO.
- Promoters:
- Dr. Ashish Narayan Sakalkar
- Mrs. Saili Jayaram More
- Mr. Sachin Chandrakant Badakh
- Background:
- Technical and pharma marketing experience.
- Experience in handling overseas regulatory registrations.
- Promoter Holding:
- Pre-IPO: Not explicitly mentioned.
- Post-IPO: Will be diluted due to fresh issue.
- Controversies:
- ✅ No reported legal, financial, or regulatory issues.
Objects of the Issue
The IPO proceeds will be used for working capital needs, general corporate purposes, and issue-related expenses. There is no Offer for Sale (OFS) component, indicating full funds benefit the company.
Proceeds of the IPO will be used for:
- Working Capital Requirements.
- General Corporate Purposes.
- Issue-related Expenses.
Asston Pharmaceuticals IPO Registrar
Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
IPO Lead Managers aka Merchant Bankers
- Sobhagya Capital Options Ltd
Company Address
Asston Pharmaceuticals Limited
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/
Asston Pharmaceuticals IPO FAQs
What does Asston Pharmaceuticals do?
Manufactures and exports pharmaceutical formulations and nutraceuticals.
When Asston Pharmaceuticals IPO will open for subscription?
The IPO is to open on July 9, 2025 for QIB, NII, and Retail Investors. The IPO will close on July 11, 2025.
What is Asston Pharmaceuticals IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
What is Asston Pharmaceuticals IPO Issue Size?
Asston Pharmaceuticals IPO issue size is ₹27.56 crores.
What is Asston Pharmaceuticals IPO Price Band?
Asston Pharmaceuticals IPO Price Band is ₹115 to ₹123.
What is Asston Pharmaceuticals IPO Lot Size?
The minimum bid is 2000 Shares with ₹2,46,000 amount.
What is the Asston Pharmaceuticals IPO Allotment Date?
Asston Pharmaceuticals IPO allotment date is July 14, 2025.
What is the Asston Pharmaceuticals IPO Listing Date?
Asston Pharmaceuticals IPO listing date is July 16, 2025. The IPO is to list on BSE.